CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer

Lancet

Volumn 352, Issue 9137, 1998, Pages 1358-

  Höltl, Lorenz ^b   Rieser, Claudia ^b   Papesh, Christine ^b   Ramoner, Reinhold ^b   Bartsch, Georg ^b   Thurnher, Martin ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; CD83; KEYHOLE LIMPET HEMOCYANIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; HELPER CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MALE; METASTASIS; PRIORITY JOURNAL;

EID: 0032564140     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60748-9     Document Type: Article

References (5)

1. 1 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
2. 2 Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
3. 3 Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-80.
4. 4 Rieser C, Böck G, Klocker H, Bartsch G, Thurnher M. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 1997; 186: 1603-08.
5. 5 Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75.